1. Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Issue 12 (December 2018) Authors: Deng, Qinfang; Xie, Boxiong; Wu, Leilei; Ji, Xianxiu; Li, Chao; Feng, Li; Fang, Qiyu; Bao, Yuchen; Li, Jialu; Jin, Shengnan; Ding, Chunming; Li, Yixue; Zhou, Songwen Journal: Heliyon Issue: Volume 4:Issue 12(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer. Issue 2 (February 2021) Authors: Ji, Xianxiu; Xie, Huikang; Zhu, Ren; Chen, Bin; Jiang, Sen; Luo, Jie Journal: Journal of international medical research Issue: Volume 49:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. HS3ST1 Promotes Non-Small-Cell Lung Cancer Progression by Targeting the SPOP/FADD/NF-κB Pathway. (19th July 2022) Authors: Ji, Xianxiu; Cheng, Kebin; Gao, Caixia; Xie, Huikang; Zhu, Ren; Luo, Jie Other Names: Liao Zhijun Academic Editor. Journal: BioMed research international Issue: Volume 2022(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Special issue "The advance of solid tumor research in China": Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China. Issue 1 (17th June 2022) Authors: Su, Chunxia; Zhou, Juan; Qiang, Huiping; Zhao, Jing; Chang, Qing; Ji, Xianxiu; Li, Jiaqi; Xie, Mengqing; Chu, Tianqing Other Names: Qin Shuqui guestEditor.; Li Jin guestEditor.; Guo Jun guestEditor.; Ma Jun guestEditor.; Zhou Caicun guestEditor. Journal: International journal of cancer Issue: Volume 152:Issue 1(2023) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗